论文部分内容阅读
目的探讨自身癌细胞抗原(Ag)激活的树突状细胞(DC)联合细胞因子诱导杀伤细胞(CIK)在晚期前列腺癌免疫治疗中的临床疗效。方法回顾性研究48例诊断明确且不再适宜手术或放化疗的晚期激素难治性前列腺癌(HRPC)患者,配对分成两组:对照组24例,接受内科保守治疗;免疫组24例,同时给予内科治疗和Ag-DC-CIK过继免疫,记录两组患者的临床疗效。结果治疗后免疫组患者的细胞免疫功能[外周血淋巴细胞银染核仁区比值5.14±2.34,外周血IL-12含量(73.54±21.63)pg/ml]、生活质量(体力状况PS评分2.08±0.69)和生存时间(1年生存率66.66%,中位生存时间16.63个月,中位疾病进展时间12.31个月)等疗效指标均明显优于对照组[相应结果分别为4.02±1.93,(59.63±12.66)pg/ml,2.62±1.05,33.33%,9.85个月,7.24个月],两组之间差异有统计学意义(P<0.05)。结论 Ag-DC-CIK过继免疫能使晚期HRPC患者获益,具有较好的临床应用价值。
Objective To investigate the clinical efficacy of dendritic cells (DC) combined with cytokine-induced killer cells (CIKs) activated by its own cancer cell antigen (Ag) in the immunotherapy of advanced prostate cancer. Methods A retrospective study of 48 patients with advanced hormone refractory prostate cancer (HRPC) diagnosed and no longer suitable for surgery or radiotherapy and chemotherapy was divided into two groups: control group (24 cases) received conservative treatment and immunization group (24 cases) Medical treatment and Ag-DC-CIK adoptive immunity were given, and the clinical efficacy was recorded in both groups. Results The cellular immune function of the immunized group [5.14 ± 2.34 (73.54 ± 21.63) pg / ml) in peripheral blood and the quality of life (PS score 2.08 ± 0.69) and survival time (1 year survival rate 66.66%, median survival time 16.63 months, median disease progression time 12.31 months) were significantly better than the control group [corresponding results were 4.02 ± 1.93, (59.63 ± 12.66) pg / ml, 2.62 ± 1.05, 33.33%, 9.85 months and 7.24 months respectively. There was a significant difference between the two groups (P <0.05). Conclusion Adoptive Ag-DC-CIK immunization can benefit patients with advanced HRPC and has good clinical value.